Organon & Co. (NYSE:OGN) Reaches New 52-Week High – Here’s Why

Organon & Co. (NYSE:OGN) hit a new 52-week high on Tuesday . The company traded as high as $13.78 and last traded at $13.7750, with a volume of 4872488 shares changing hands. The stock had previously closed at $13.78.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. Five investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Stock Performance

The firm has a market capitalization of $3.59 billion, a price-to-earnings ratio of 17.77, a P/E/G ratio of 1.27 and a beta of 1.52. The company has a 50-day moving average price of $13.63 and a 200-day moving average price of $11.47. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 10.39%.

Institutional Trading of Organon & Co.

Institutional investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC acquired a new position in shares of Organon & Co. during the second quarter valued at approximately $267,000. Tidal Investments LLC lifted its position in Organon & Co. by 18.1% in the second quarter. Tidal Investments LLC now owns 285,099 shares of the company’s stock worth $3,860,000 after purchasing an additional 43,687 shares during the period. WINTON GROUP Ltd bought a new position in Organon & Co. during the 2nd quarter valued at $6,904,000. Engineers Gate Manager LP acquired a new position in shares of Organon & Co. during the 2nd quarter valued at $713,000. Finally, Maven Securities LTD bought a new stake in shares of Organon & Co. in the 2nd quarter worth $5,879,000. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.